Fungal infections:

Indications for: CRESEMBA

Invasive aspergillosis. Invasive mucormycosis.

Adult Dosage:

Swallow whole. ≥18yrs: loading dose: 372mg every 8hrs for 6 doses (48hrs); maintenance dose: 372mg once daily starting 12–24hrs after the last loading dose.

Children Dosage:

<18yrs: not established.

CRESEMBA Contraindications:

Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, high-dose ritonavir [400mg every 12hrs]). Concomitant strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John's wort, long-acting barbiturates). Familial short QT syndrome.

CRESEMBA Warnings/Precautions:

Perform liver-related lab tests at the start of and during therapy; monitor for more severe hepatic injury if abnormal test results. Discontinue if liver disease, infusion-related reactions (including hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia), or severe cutaneous reactions develop. Azole hypersensitivity. Severe hepatic impairment (Child-Pugh Class C). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 28 days after the last dose. Pregnancy. Nursing mothers: not recommended.

CRESEMBA Classification:

Azole antifungal.

CRESEMBA Interactions:

See Contraindica­tions. Caution with concomitant lopinavir/ritonavir, atorvastatin (monitor), midazolam (consider dose reduction), bupropion (consider dose increase), mycophenolate mofetil (monitor for MPA-related toxicities), digoxin (monitor). Concomitant cyclosporine, sirolimus, tacrolimus; monitor and adjust dose as needed.

Adverse Reactions:

Nausea, vomiting, diarrhea, headache, elevated liver chemistry tests, hypokalemia, constipation, dyspnea, cough, peripheral edema, back pain.

Generic Drug Availability:


How Supplied:

Blister packs—7; Single-dose vial—1

Pricing for CRESEMBA

7 capsules of 186mg dose pack (Qty: 8)
Appx. price $5182